Watchman in the Real World: Reports on Use in High-Risk …
https://consultqd.clevelandclinic.org/watchman-in-the-real-world-reports-on-use-in-high-risk-patients-and-overall-safety/
WebMay 11, 2018 · Higher stroke risk, greater benefit? In the PREVAIL trial, the Watchman was noninferior to warfarin for ischemic stroke prevention or systemic embolization after seven days, one of two co-primary end points for efficacy. Overall noninferiority — the other co-primary efficacy endpoint — wasn’t achieved.
DA: 51 PA: 5 MOZ Rank: 24